TickerFacts.

A business in context

NTLA research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-02 · 0001193125-26-415541

  2. 8-K · Current report

    Report date 2026-09-08 · 0001193125-26-385194 · Items 7.01,8.01,9.01

  3. 8-K · Current report

    Report date 2026-09-04 · 0001193125-26-383645 · Items 1.01,2.03,7.01,9.01

  4. 4 · Ownership change

    Report date 2026-08-20 · 0001193125-26-363567

  5. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-337952

  6. 8-K · Current report

    Report date 2026-08-06 · 0001193125-26-336772 · Items 2.02,9.01

  7. 4 · Ownership change

    Report date 2026-07-22 · 0001193125-26-316279

  8. 4 · Ownership change

    Report date 2026-07-01 · 0002019493-26-000002

  9. 4 · Ownership change

    Report date 2026-07-02 · 0001821530-26-000002

  10. 8-K · Current report

    Report date 2026-06-13 · 0001193125-26-270358 · Items 7.01,8.01,9.01

  11. 4 · Ownership change

    Report date 2026-06-09 · 0001756929-26-000002

  12. 4 · Ownership change

    Report date 2026-06-09 · 0001563572-26-000001

  13. 4 · Ownership change

    Report date 2026-06-09 · 0001545794-26-000001

  14. 8-K · Current report

    Report date 2026-06-09 · 0001193125-26-265934 · Items 5.07

  15. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-215740

  16. 8-K · Current report

    Report date 2026-05-11 · 0001193125-26-215721 · Items 2.02,9.01

  17. 8-K · Current report

    Report date 2026-04-27 · 0001193125-26-197489 · Items 1.01,2.02,9.01

  18. DEF 14A · Proxy statement

    Report date 2026-06-09 · 0001193125-26-197283

  19. 8-K · Current report

    Report date 2026-04-27 · 0001193125-26-179401 · Items 7.01,8.01,9.01

  20. 8-K · Current report

    Report date 2026-04-07 · 0001193125-26-151300 · Items 5.03,9.01

  21. 8-K · Current report

    Report date 2026-03-02 · 0001193125-26-084309 · Items 1.01,7.01,8.01,9.01

  22. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-076550

  23. 8-K · Current report

    Report date 2026-02-26 · 0001193125-26-073456 · Items 2.02,9.01

  24. 8-K · Current report

    Report date 2026-01-27 · 0001193125-26-023387 · Items 7.01,8.01,9.01

  25. 8-K · Current report

    Report date 2026-01-09 · 0001193125-26-008307 · Items 7.01,8.01,9.01

  26. 8-K · Current report

    Report date 2025-11-08 · 0001193125-25-274596 · Items 7.01,8.01,9.01

  27. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-269680

  28. 8-K · Current report

    Report date 2025-11-06 · 0001193125-25-269479 · Items 2.02,9.01

  29. 8-K · Current report

    Report date 2025-10-29 · 0001193125-25-256378 · Items 8.01

  30. 8-K · Current report

    Report date 2025-10-27 · 0001193125-25-250757 · Items 7.01,8.01,9.01

  31. 8-K · Current report

    Report date 2025-09-25 · 0001193125-25-217484 · Items 7.01,8.01,9.01

  32. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-104987

  33. 8-K · Current report

    Report date 2025-08-07 · 0000950170-25-104574 · Items 2.02,5.02,9.01

  34. 8-K · Current report

    Report date 2025-06-15 · 0001193125-25-141087 · Items 7.01,8.01,9.01

  35. 8-K · Current report

    Report date 2025-06-11 · 0000950170-25-085479 · Items 5.02,5.07,9.01

  36. 8-K · Current report

    Report date 2025-05-28 · 0001193125-25-129524 · Items 7.01,8.01

  37. 8-K · Current report

    Report date 2025-05-18 · 0001193125-25-122076 · Items 7.01,8.01,9.01

  38. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-066914

  39. 8-K · Current report

    Report date 2025-05-08 · 0000950170-25-066403 · Items 2.02,9.01

  40. DEF 14A · Proxy statement

    Report date 2025-06-11 · 0000950170-25-061023

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 5 transaction rows5SGrant / award: 0 transaction rows0AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

5 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-08-21
2026-08-24
LEONARD JOHN MS · Sale
Disposed
Common Stock2785.013.0
2026-08-20
2026-08-24
LEONARD JOHN MS · Sale
Disposed
Common Stock19890.012.6
2026-07-22
2026-07-24
Dulac Edward J IIIS · Sale
Disposed
Common Stock8111.011.25
2026-07-02
2026-07-06
Dulac Edward J IIIS · Sale
Disposed
Common Stock4677.018.0
2026-07-01
2026-07-06
Dube Michael PS · Sale
Disposed
Common Stock2641.016.78

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001652130Intellia Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

Legal Entity Identifier
5493002T5BCPE5DZC723
GLEIF legal name
INTELLIA THERAPEUTICS, INC.
Entity / LEI registration status
ACTIVE / LAPSED
Reference data updated
2026-09-01T23:30:21Z

direct-parent: no parent LEI supplied

ultimate-parent: no parent LEI supplied

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Intellia Therapeutics · alias · wikidata
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$57.88M$62.17M
2023-12-31$36.27M$40.11M
2022-12-31$52.12M$60.00M
2021-12-31$33.05M$41.09M
2020-12-31$57.99M$75.50M
2019-12-31$43.10M$56.80M
2018-12-31$30.43M$40.84M
2017-12-31$26.12M$35.90M

Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

Explore the CPI history ↗